Company Information
USD
4.56
- (2.7%)
NASDAQ:ANNX, ANNEXON, INC.
Industry: Biotechnology
End of Day: 19 April 2024 GMT-4
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Annexon's product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; and ANX009, for systemic autoimmune diseases.
Address
1400 Sierra Point Parkway
Suite 200, Building C
Website
Classification
Sector
Healthcare
Industry Group
Biotechnology
Industry
Biotechnology
Key Executives
Dr. Dean Richard Artis, PhD
Chief Scientific Officer
Mr. Thomas G. Wiggans
Chairman of the Board/Director
Ms. Jennifer Lew
CFO/Chief Accounting Officer/Executive VP
Mr. Muneer A. Satter
Director
Mr. Ted Yednock,PhD
Executive VP/Other Executive Officer
Mr. William D. Waddill
Director
Ms. Jung E. Choi
Director
Mr. Douglas Love, Esq.
CEO/Director/President
Mr. Michael Overdorf
Executive VP/Other Executive Officer
Dr. William H. Carson, M.D.
Director
Ms. Bettina M. Cockroft
Director
Ownership
Institution Holdings
FMR Inc
9,685,401 (12.374%)
FMR LLC
9,685,401 (12.374%)
Bain Capital Life Sciences Investors, LLC
8,061,719 (10.299%)
SATTER MANAGEMENT CO., L.P.
7,406,024 (9.462%)
Fidelity Management & Research Company LLC
5,299,114 (6.770%)
Adage Capital Partners Gp LLC
4,999,975 (6.388%)
Logos Global Management LP
4,950,000 (6.324%)
Redmile Group, LLC
3,503,190 (4.476%)
Fairmount Funds Management LLC
3,358,563 (4.291%)
BlackRock Inc
3,318,579 (4.240%)
Individual Holdings
Mr. Douglas Love, Esq.
196,121 (0.251%)
Dr. Dean Richard Artis, PhD
89,329 (0.114%)
Mr. Michael Overdorf
85,641 (0.109%)
Ms. Jennifer Lew
82,058 (0.105%)
Mr. Ted Yednock,PhD
72,471 (0.093%)
Funds Holdings
Fidelity Growth Company Commingled Pool
2,365,164 (3.022%)
Fidelity Growth Company Fund
1,813,286 (2.317%)
iShares Russell 2000 ETF
1,085,327 (1.387%)
Pictet - Biotech
1,071,584 (1.369%)
Pictet - Global Megatrend Selection
650,559 (0.831%)
Fidelity Growth Company K6 Fund
549,442 (0.702%)
Kennedy Extended Small Cap
524,840 (0.671%)
Fidelity Series Growth Company Fund
458,745 (0.586%)
Fidelity Small Cap Index Fund
453,786 (0.580%)
iShares Russell 2000 Value ETF
445,537 (0.569%)
Make Smart Investment Choices